Cargando…
Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
Oncology immunotherapy has been a significant advancement in cancer treatment and involves harnessing and redirecting a patient’s immune response towards their own tumour. Specific recognition and elimination of tumour cells was first proposed over a century ago with Paul Erlich’s ‘magic bullet’ the...
Autores principales: | Abbott, Rebecca C., Cross, Ryan S., Jenkins, Misty R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014258/ https://www.ncbi.nlm.nih.gov/pubmed/31947597 http://dx.doi.org/10.3390/ijms21020515 |
Ejemplares similares
-
Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023) -
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
por: Kuo, Yi-Chiu, et al.
Publicado: (2022) -
In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
por: Sun, Zhichen, et al.
Publicado: (2022) -
Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2022) -
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
por: Song, De-Gang, et al.
Publicado: (2016)